U.S. markets closed

Inhibikase Therapeutics, Inc. (IKT)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.1900-0.0600 (-2.67%)
At close: 04:00PM EDT
2.2000 +0.01 (+0.46%)
After hours: 07:36PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

    Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company will meet wi

  • Simply Wall St.

    Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

    Inhibikase Therapeutics ( NASDAQ:IKT ) Full Year 2023 Results Key Financial Results Net loss: US$19.0m (loss widened by...

  • Insider Monkey

    Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript

    Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript March 28, 2024 Inhibikase Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Greetings, and welcome to Inhibikase Therapeutics Fourth Quarter and […]